Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veru Inc VERU

Consumer Defensive Household & Personal Products
Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI... see more

Recent & Breaking News (NDAQ:VERU)

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

GlobeNewswire 1 day ago

Veru Announces Date of 2024 Annual Meeting of Shareholders

GlobeNewswire April 1, 2024

Veru Reschedules Annual Meeting of Shareholders

GlobeNewswire March 22, 2024

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

GlobeNewswire March 12, 2024

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

GlobeNewswire February 27, 2024

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

GlobeNewswire February 20, 2024

Veru Reports Fiscal 2024 First Quarter Financial Highlights

GlobeNewswire February 8, 2024

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

GlobeNewswire February 6, 2024

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire January 31, 2024

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

GlobeNewswire January 25, 2024

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

GlobeNewswire January 8, 2024

Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

GlobeNewswire December 19, 2023

VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire December 14, 2023

Veru Announces Pricing of Public Offering of Common Stock

GlobeNewswire December 14, 2023

Veru Announces Proposed Public Offering of Common Stock

GlobeNewswire December 13, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Veru Inc. - VERU

PR Newswire November 19, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Veru Inc. - VERU

Newsfile November 17, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Veru Inc. - VERU

Accesswire November 16, 2023

VERU INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Veru Inc. - VERU

Business Wire October 16, 2023

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study

GlobeNewswire October 4, 2023